MX2021012251A - Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc). - Google Patents

Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc).

Info

Publication number
MX2021012251A
MX2021012251A MX2021012251A MX2021012251A MX2021012251A MX 2021012251 A MX2021012251 A MX 2021012251A MX 2021012251 A MX2021012251 A MX 2021012251A MX 2021012251 A MX2021012251 A MX 2021012251A MX 2021012251 A MX2021012251 A MX 2021012251A
Authority
MX
Mexico
Prior art keywords
region
modified
protein
purifying
modified antibody
Prior art date
Application number
MX2021012251A
Other languages
English (en)
Inventor
Yuichiro Shimizu
Masahiro Fukunaga
Tetsuya Wakabayashi
Eiji Majima
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2021012251A publication Critical patent/MX2021012251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente invención, se encontró una resina purificada por afinidad que tiene suficiente afinidad de unión por una región Fc modificada que tiene una capacidad de unión con proteína A reducida. Específicamente, se purificó con éxito inmunoglobulina que contiene una región Fc modificada que tiene capacidad de unión con proteína A reducida, caracterizado porque un ligando modificado con proteína A que incluye una estructura en la que se ha sustituido un aminoácido del dominio C sirve como ligando Fc.
MX2021012251A 2019-04-10 2020-04-09 Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc). MX2021012251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019074738 2019-04-10
PCT/JP2020/015904 WO2020209318A1 (ja) 2019-04-10 2020-04-09 Ｆｃ領域改変抗体の精製方法

Publications (1)

Publication Number Publication Date
MX2021012251A true MX2021012251A (es) 2021-11-12

Family

ID=72752051

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012251A MX2021012251A (es) 2019-04-10 2020-04-09 Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc).

Country Status (13)

Country Link
US (1) US20220213140A1 (es)
EP (1) EP3954696A4 (es)
JP (1) JPWO2020209318A1 (es)
KR (1) KR20210149779A (es)
CN (1) CN113906042A (es)
AU (1) AU2020273072A1 (es)
BR (1) BR112021020204A2 (es)
CA (1) CA3136398A1 (es)
IL (1) IL286982A (es)
MX (1) MX2021012251A (es)
SG (1) SG11202110986YA (es)
TW (1) TW202104244A (es)
WO (1) WO2020209318A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US10000560B2 (en) 2014-12-19 2018-06-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
RU2139351C1 (ru) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CN101014619B (zh) 2004-07-15 2010-11-03 赞科股份有限公司 优化的Fc变体
KR101027427B1 (ko) 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
PL1752471T3 (pl) 2005-01-05 2009-04-30 F Star Biotechnologische Forschungs Und Entw M B H Syntetyczne domeny immunoglobulinowe o właściwościach wiążących konstruowanych w regionach cząsteczki różnych od regionów determinujących komplementarność
WO2007097361A1 (ja) * 2006-02-21 2007-08-30 Protenova Co., Ltd. イムノグロブリン親和性リガンド
JP4179517B2 (ja) 2006-02-21 2008-11-12 プロテノバ株式会社 イムノグロブリン親和性リガンド
IN2014DN10515A (es) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
MX2010003450A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
ES2532461T3 (es) 2007-12-26 2015-03-27 Xencor, Inc. Variantes de FC con enlazamiento alterado a FCRN
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
JP5229888B2 (ja) * 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
WO2012133349A1 (ja) * 2011-03-25 2012-10-04 株式会社カネカ アフィニティー分離マトリックス用タンパク質
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN110639014A (zh) 2011-09-30 2020-01-03 中外制药株式会社 促进抗原消除的抗原结合分子
US20150166654A1 (en) 2012-05-30 2015-06-18 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
DK2857419T3 (da) 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til eliminering af aggregerede antigener
WO2014145159A2 (en) 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JP6153801B2 (ja) 2013-07-23 2017-06-28 旭化成ホームズ株式会社 ノズル
EP3042912A4 (en) * 2013-09-04 2017-05-03 Protenova Co., Ltd. Immunoglobulin-binding domain multimer
JP2015185254A (ja) 2014-03-20 2015-10-22 日立マクセル株式会社 非水電解質二次電池
US10000560B2 (en) * 2014-12-19 2018-06-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
TWI605057B (zh) 2015-12-18 2017-11-11 中外製藥股份有限公司 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法

Also Published As

Publication number Publication date
EP3954696A4 (en) 2023-07-26
BR112021020204A2 (pt) 2021-12-07
KR20210149779A (ko) 2021-12-09
CN113906042A (zh) 2022-01-07
WO2020209318A1 (ja) 2020-10-15
US20220213140A1 (en) 2022-07-07
IL286982A (en) 2021-12-01
JPWO2020209318A1 (es) 2020-10-15
AU2020273072A1 (en) 2021-12-09
EP3954696A1 (en) 2022-02-16
CA3136398A1 (en) 2020-10-15
SG11202110986YA (en) 2021-11-29
TW202104244A (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
MX2021012251A (es) Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc).
WO2018134235A8 (en) Improved serum albumin binders
MX347818B (es) Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
MX2023007520A (es) Aglutinantes de albumina de suero mejorados.
MX2024008521A (es) Aglutinantes de albumina serica mejorados.
EP4324840A3 (en) Novel alkaline stable immunoglobulin-binding proteins
EA201791742A1 (ru) Антитела, направленные против гена-3 активации лимфоцитов (lag-3)
WO2017085172A3 (en) Improved serum albumin binders
MA38498A1 (fr) Protéines de liaison anti-lag-3
UA86605C2 (ru) Антитело, которое содержит вариант исходного человеческого fс-участка
SG10201805584YA (en) ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
MX2023006291A (es) Metodos para purificar proteinas que contienen fc.
MX2020000288A (es) Cromatografia.
MY188469A (en) Low affinity blood brain barrier receptor antibodies and uses therefor
ATE525087T1 (de) Verfahren zur aufreinigung von antikörpern
EP4371996A3 (en) Methods for purifying antibodies
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
PE20230348A1 (es) Variantes de anticuerpos felinos
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
EP4349853A3 (en) Novel triple-helical polypeptides lacking binding affinity for the fc domain of immunoglobulin and uses thereof
BR112021023540A2 (pt) Agentes de afinidade
BR112014019773A8 (pt) Ligantes para anticorpo e proteína de fusão fc para cromatografia de afinidade
MX2021015669A (es) Anticuerpos para la unión a psma.
MX2018005831A (es) Gradientes de ph-sal opuestos para separaciones de proteina mejoradas.
MX2021013441A (es) Molecula de union a antigenos, composicion farmaceutica y metodo.